DiaMedica Therapeutics Croissance future
Future contrôle des critères 0/6
Les bénéfices de DiaMedica Therapeutics devraient diminuer de 8.2% par an tandis que son chiffre d'affaires annuel devrait croître de 74.6% par an. Le BPA devrait croître de en hausse de 2.4% par an.
Informations clés
-8.2%
Taux de croissance des bénéfices
2.43%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.2% |
| Taux de croissance des recettes | 74.6% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 08 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Companies Like DiaMedica Therapeutics (NASDAQ:DMAC) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Preeclampsia Breakthrough Potential And Strong Cash Runway Will Support Future Value Creation
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a KLK1 protein therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?
Preeclampsia And Stroke Programs Will Drive Long Term Potential For This Biotech
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a recombinant KLK1 therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
DiaMedica Therapeutics (NASDAQ:DMAC) on Wednesday said the U.S. FDA had placed a clinical hold on its phase 2/3 trial evaluating its product candidate DM199 for the treatment of a type of stroke called acute ischemic stroke. The trial, called ReMEDy2, was put on hold as three serious cases of low blood pressure in stroke patients were reported after they received an injection of DM199. The company said it had paused patient enrollment, and believes the low blood pressure events were due to the use of a different intravenous bag in the ReMEDy2 trial from the one used in the prior ReMEDy1 trial. "...the company is confirming the differences in drug absorption in the IV bags used in the ReMEDy1 trial compared to the ReMEDy2 trial and plans to work with the FDA to modify the ReMEDy2 trial protocol to adjust the DM199 IV dosing to more closely match the dosing in the ReMEDy1 trial, taking into account these differences", DMAC said. DMAC said that no such low blood pressure issues were reported in the ReMEDy1 trial.We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
DMAC is a microcap biotech that has the first potential breakthrough stroke drug in 25 years, which addresses a $3.5 billion U.S. market. They initiated a phase 2/3 pivotal trial. Their drug, DM199, is the first synthetic version of a naturally occurring protein, KLK1. Porcine and human-derived KLK1 have been used for 20+ years in Asia to treat stroke/kidney disease. A near-term Asian strategic partner could provide a $5-$20 million upfront payment with a potential of $50+ million in milestone payments for DM199 distribution rights. Insider buying of 110K+ shares in Q3-2021 is a very positive signal. The average price target from 5 Wall Street analysts is $22, or 5x the current price. A recent capital raise eliminates concern over any future dilution. No capital should be needed until mid-2023 after the pivotal stroke study results are released and the kidney indications.Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 5 | -76 | -67 | N/A | 3 |
| 12/31/2027 | N/A | -57 | -60 | -43 | 5 |
| 12/31/2026 | N/A | -46 | -46 | -40 | 5 |
| 3/31/2026 | N/A | -35 | -31 | -31 | N/A |
| 12/31/2025 | N/A | -33 | -29 | -29 | N/A |
| 9/30/2025 | N/A | -32 | -28 | -28 | N/A |
| 6/30/2025 | N/A | -30 | -26 | -26 | N/A |
| 3/31/2025 | N/A | -27 | -23 | -23 | N/A |
| 12/31/2024 | N/A | -24 | -22 | -22 | N/A |
| 9/30/2024 | N/A | -22 | -19 | -19 | N/A |
| 6/30/2024 | N/A | -20 | -20 | -20 | N/A |
| 3/31/2024 | N/A | -19 | -20 | -20 | N/A |
| 12/31/2023 | N/A | -19 | -19 | -19 | N/A |
| 9/30/2023 | N/A | -18 | -18 | -18 | N/A |
| 6/30/2023 | N/A | -17 | -15 | -15 | N/A |
| 3/31/2023 | N/A | -15 | -13 | -13 | N/A |
| 12/31/2022 | N/A | -14 | -12 | -12 | N/A |
| 9/30/2022 | N/A | -13 | -12 | -12 | N/A |
| 6/30/2022 | N/A | -14 | -12 | -12 | N/A |
| 3/31/2022 | N/A | -13 | -12 | -12 | N/A |
| 12/31/2021 | N/A | -14 | -12 | -12 | N/A |
| 9/30/2021 | N/A | -15 | -13 | -12 | N/A |
| 6/30/2021 | N/A | -14 | -12 | -12 | N/A |
| 3/31/2021 | N/A | -13 | -11 | -11 | N/A |
| 12/31/2020 | N/A | -12 | -9 | -9 | N/A |
| 9/30/2020 | N/A | -11 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -10 | -7 | -7 | N/A |
| 3/31/2020 | N/A | -10 | -9 | -9 | N/A |
| 12/31/2019 | N/A | -11 | N/A | -9 | N/A |
| 9/30/2019 | N/A | -10 | N/A | -9 | N/A |
| 6/30/2019 | 1 | -9 | N/A | -10 | N/A |
| 3/31/2019 | 1 | -8 | N/A | -8 | N/A |
| 12/31/2018 | 1 | -6 | N/A | -6 | N/A |
| 9/30/2018 | 1 | -5 | N/A | -5 | N/A |
| 6/30/2018 | N/A | -4 | N/A | -4 | N/A |
| 3/31/2018 | N/A | -4 | N/A | -4 | N/A |
| 12/31/2017 | N/A | -4 | N/A | -4 | N/A |
| 9/30/2017 | N/A | -4 | N/A | -4 | N/A |
| 6/30/2017 | N/A | -4 | N/A | -4 | N/A |
| 3/31/2017 | N/A | -3 | N/A | -3 | N/A |
| 12/31/2016 | N/A | -2 | N/A | -3 | N/A |
| 9/30/2016 | N/A | -2 | N/A | -2 | N/A |
| 6/30/2016 | N/A | -2 | N/A | -2 | N/A |
| 3/31/2016 | N/A | -1 | N/A | -2 | N/A |
| 12/31/2015 | N/A | -2 | N/A | -2 | N/A |
| 9/30/2015 | N/A | -2 | N/A | -1 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: DMAC devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: DMAC devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: DMAC devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: DMAC ne devrait pas générer de revenus l'année prochaine.
Croissance élevée des revenus: DMAC ne devrait pas générer de revenus l'année prochaine.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de DMAC devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/18 20:10 |
| Cours de l'action en fin de journée | 2026/05/15 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
DiaMedica Therapeutics Inc. est couverte par 13 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Kyle Bauser | Colliers Securities |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |